四价HPV疫苗接种后10年单剂免疫应答评价
研究比较接种1剂、2剂或3剂四价HPV疫苗后10年的免疫应答,单剂受试者抗体水平在接种后18个月趋于稳定,虽显著低于3剂但显著高于未接种自然感染女性,与单剂对持续性HPV 16/18感染的高疫苗效力相关。
要点
- 单剂四价HPV疫苗受试者接种后120个月内抗体水平稳定,18个月后达平台期。
- 单剂抗体滴度显著低于3剂(GMT比值下限<0.5),但显著高于未接种自然感染女性(GMT比值2.05至4.04倍)。
- 单剂免疫应答持久性与既往报告的单剂对持续性HPV 16/18感染高疫苗效力相关。
核心结论
- 研究显示单剂四价HPV疫苗受试者在接种后10年具有高且持久的免疫应答。
研究设计与样本
- 受试者在10至18岁时接种1剂、2剂或3剂四价HPV疫苗,从便利样本中于接种后不同时间点至10年采集血清学样本,并与年龄匹配的未接种女性单时间点样本比较。
主要发现
- 单剂受试者抗体应答动态在120个月内观察显示,所有四种HPV型别在接种后18个月抗体水平稳定。
- 单剂接种后HPV型别特异性(结合或中和)抗体滴度显著低于3剂接种(GMT比值下限<0.5)。
- 单剂接种后抗体滴度均显著高于未接种女性自然感染后观察到的水平(GMT比值高2.05至4.04倍)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income countries to introduce the vaccine. From a programmatic perspective the durability of protection offered by a single-dose will be a key consideration. The primary objectives of the present study were to determine whether recipients of a single-dose of quadrivalent HPV vaccine had sustained immune response against targeted HPV types (HPV 6,11,16,18) at 10 years post-vaccination and whether this response was superior to the natural antibody titres observed in unvaccinated women. METHODS: Participants received at age 10-18 years either one, two or three doses of the quadrivalent HPV vaccine. Serology samples were obtained at different timepoints up to 10 years after vaccination from a convenience sample of vaccinated participants and from age-matched unvaccinated women at one timepoint. The evolution of the binding and neutralizing antibody response was presented by dose received. 10-year durability of immune responses induced by a single-dose was compared to that after three doses of the vaccine and in unvaccinated married women. RESULTS: The dynamics of antibody response among the single-dose recipients observed over 120 months show stabilized levels 18 months after vaccination for all four HPV types. Although the HPV type-specific (binding or neutralizing) antibody titres after a single-dose were significantly inferior to those after three doses of the vaccine (lower bounds of GMT ratios < 0.5), they were all significantly higher than those observed in unvaccinated women following natural infections (GMT ratios: 2.05 to 4.04-fold higher). The results correlate well with the high vaccine efficacy of single-dose against persistent HPV 16/18 infections reported by us earlier at 10-years post-vaccination. CONCLUSION: Our study demonstrates the high and durable immune response in single-dose recipients of HPV vaccine at 10-years post vaccination.
引用
- Joshi S, Anantharaman D, Muwonge R, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2022. PMID: 36446654. doi:10.1016/j.vaccine.2022.11.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。